S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
3 Blue Chip Safe Havens to Shield Your Portfolio
BREAKING: Tiny biotech successfully treats blindness (Ad)
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
Are Gene Therapy Stocks The Market's Next Big Winners?
BREAKING: Tiny biotech successfully treats blindness (Ad)
3 Stocks That Flourish In The Fall
Buy The World’s Largest IT Infrastructure Provider For Under $20
Watch SHOCKING Footage of AI Facility with Ties to Elon Musk (Ad)
2 Must-Have Silicon Companies That Don't Make Microchips
Small Caps That Have Priced In A Hard Landing For Big Upside
S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
3 Blue Chip Safe Havens to Shield Your Portfolio
BREAKING: Tiny biotech successfully treats blindness (Ad)
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
Are Gene Therapy Stocks The Market's Next Big Winners?
BREAKING: Tiny biotech successfully treats blindness (Ad)
3 Stocks That Flourish In The Fall
Buy The World’s Largest IT Infrastructure Provider For Under $20
Watch SHOCKING Footage of AI Facility with Ties to Elon Musk (Ad)
2 Must-Have Silicon Companies That Don't Make Microchips
Small Caps That Have Priced In A Hard Landing For Big Upside
S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
3 Blue Chip Safe Havens to Shield Your Portfolio
BREAKING: Tiny biotech successfully treats blindness (Ad)
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
Are Gene Therapy Stocks The Market's Next Big Winners?
BREAKING: Tiny biotech successfully treats blindness (Ad)
3 Stocks That Flourish In The Fall
Buy The World’s Largest IT Infrastructure Provider For Under $20
Watch SHOCKING Footage of AI Facility with Ties to Elon Musk (Ad)
2 Must-Have Silicon Companies That Don't Make Microchips
Small Caps That Have Priced In A Hard Landing For Big Upside
S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
3 Blue Chip Safe Havens to Shield Your Portfolio
BREAKING: Tiny biotech successfully treats blindness (Ad)
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
Are Gene Therapy Stocks The Market's Next Big Winners?
BREAKING: Tiny biotech successfully treats blindness (Ad)
3 Stocks That Flourish In The Fall
Buy The World’s Largest IT Infrastructure Provider For Under $20
Watch SHOCKING Footage of AI Facility with Ties to Elon Musk (Ad)
2 Must-Have Silicon Companies That Don't Make Microchips
Small Caps That Have Priced In A Hard Landing For Big Upside

BridgeBio Pharma (BBIO) Stock Forecast, Price & News

$27.08
-0.19 (-0.70%)
(As of 09/25/2023 ET)
Compare
Today's Range
$26.22
$27.75
50-Day Range
$26.97
$35.01
52-Week Range
$6.64
$36.36
Volume
2.86 million shs
Average Volume
2.71 million shs
Market Capitalization
$4.40 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$37.30

BridgeBio Pharma MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.90 Rating Score
Upside/​Downside
37.7% Upside
$37.30 Price Target
Short Interest
Bearish
13.12% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.31
Upright™ Environmental Score
News Sentiment
0.51mentions of BridgeBio Pharma in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$54.62 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($3.53) to ($2.93) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.66 out of 5 stars

Medical Sector

79th out of 963 stocks

Pharmaceutical Preparations Industry

20th out of 447 stocks


BBIO stock logo

About BridgeBio Pharma (NASDAQ:BBIO) Stock

BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1; and BBP-711 for the treatment of hyperoxaluria, as well as patients suffering from recurrent kidney stones. In addition, it engages in developing products for Mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and The Regents of the University of California; Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

BBIO Price History

BBIO Stock News Headlines

BridgeBio Pharma Announces $250 Mln PIPE Financing
The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
BridgeBio Pharma (NASDAQ:BBIO) Shares Gap Down to $29.62
BridgeBio Pharma (BBIO) Gets a Buy from Goldman Sachs
The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
BridgeBio Pharma Unusual Options Activity
See More Headlines
Receive BBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BridgeBio Pharma and its competitors with MarketBeat's FREE daily newsletter.

BBIO Company Calendar

Last Earnings
8/03/2023
Today
9/25/2023
Next Earnings (Estimated)
11/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BBIO
Fax
N/A
Employees
392
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$37.30
High Stock Price Forecast
$60.00
Low Stock Price Forecast
$18.00
Forecasted Upside/Downside
+37.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.90
Research Coverage
10 Analysts

Profitability

Net Income
$-481,180,000.00
Net Margins
-10,096.65%
Pretax Margin
-10,294.24%

Debt

Sales & Book Value

Annual Sales
$77.65 million
Book Value
($8.32) per share

Miscellaneous

Free Float
116,135,000
Market Cap
$4.40 billion
Optionable
Not Optionable
Beta
0.97
10 Best Stocks to Own in 2023 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2023 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Dr. Neil Kumar Ph.D. (Age 44)
    Co-Founder, Pres, CEO & Director
    Comp: $2.1M
  • Dr. Charles J. Homcy M.D. (Age 75)
    Co-Founder, Chairman of Pharmaceuticals & Independent Lead Director
    Comp: $208k
  • Dr. Brian C. Stephenson C.F.A. (Age 42)
    Ph.D., CFO & Sec.
    Comp: $1.15M
  • Dr. Richard H. Scheller Ph.D. (Age 70)
    Chairman of R&D
    Comp: $202.4k
  • Dr. Frank P. McCormick Ph.D. (Age 73)
    Co-Founder & Chairman of Oncology
  • Dr. Uma Sinha Ph.D. (Age 66)
    Chief Scientific Officer
  • Grace Rauh
    VP of Communications
  • Mr. Eli M. Wallace Ph.D. (Age 56)
    Chief Scientific Officer of Oncology
  • Dr. Thomas Trimarchi Ph.D.
    Chief Product Officer
  • Dr. Eric Michael David J.D. (Age 51)
    M.D., Ph.D., Chief Exec. Officer of Gene Therapy













BBIO Stock - Frequently Asked Questions

Should I buy or sell BridgeBio Pharma stock right now?

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BridgeBio Pharma in the last year. There are currently 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" BBIO shares.
View BBIO analyst ratings
or view top-rated stocks.

What is BridgeBio Pharma's stock price forecast for 2023?

10 Wall Street analysts have issued twelve-month price objectives for BridgeBio Pharma's shares. Their BBIO share price forecasts range from $18.00 to $60.00. On average, they anticipate the company's share price to reach $37.30 in the next twelve months. This suggests a possible upside of 37.7% from the stock's current price.
View analysts price targets for BBIO
or view top-rated stocks among Wall Street analysts.

How have BBIO shares performed in 2023?

BridgeBio Pharma's stock was trading at $7.62 at the beginning of 2023. Since then, BBIO shares have increased by 255.4% and is now trading at $27.08.
View the best growth stocks for 2023 here
.

When is BridgeBio Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our BBIO earnings forecast
.

How were BridgeBio Pharma's earnings last quarter?

BridgeBio Pharma, Inc. (NASDAQ:BBIO) announced its earnings results on Thursday, August, 3rd. The company reported ($0.98) earnings per share for the quarter, missing analysts' consensus estimates of ($0.80) by $0.18. The business earned $1.60 million during the quarter, compared to analysts' expectations of $2.99 million. The company's revenue was down 97.8% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.07) earnings per share.

What other stocks do shareholders of BridgeBio Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BridgeBio Pharma investors own include Advanced Micro Devices (AMD), Gilead Sciences (GILD), Cisco Systems (CSCO), Johnson & Johnson (JNJ), Pfizer (PFE), Roku (ROKU), Editas Medicine (EDIT), Block (SQ), Sorrento Therapeutics (SRNE) and Sarepta Therapeutics (SRPT).

When did BridgeBio Pharma IPO?

(BBIO) raised $225 million in an initial public offering on Thursday, June 27th 2019. The company issued 15,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs, Jefferies, SVB Leerink and KKR acted as the underwriters for the IPO and Piper Jaffray, Mizuho Securities, BMO Capital Markets and Raymond James were co-managers.

What is BridgeBio Pharma's stock symbol?

BridgeBio Pharma trades on the NASDAQ under the ticker symbol "BBIO."

Who are BridgeBio Pharma's major shareholders?

BridgeBio Pharma's stock is owned by a number of retail and institutional investors. Top institutional investors include Geode Capital Management LLC (1.49%), Perceptive Advisors LLC (1.08%), Northern Trust Corp (0.70%), American International Group Inc. (0.61%), Charles Schwab Investment Management Inc. (0.59%) and Cormorant Asset Management LP (0.00%). Insiders that own company stock include Brian C Stephenson, Brian C Stephenson, Cameron Turtle, Charles J Homcy, Douglas A Dachille, Genetic Disorder LP Kkr, Global Investors Lp Viking, Michael Thomas Henderson, Neil Kumar, Randal W Scott, Richard H Scheller and Ronald J Daniels.
View institutional ownership trends
.

How do I buy shares of BridgeBio Pharma?

Shares of BBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BridgeBio Pharma's stock price today?

One share of BBIO stock can currently be purchased for approximately $27.08.

How much money does BridgeBio Pharma make?

BridgeBio Pharma (NASDAQ:BBIO) has a market capitalization of $4.40 billion and generates $77.65 million in revenue each year. The company earns $-481,180,000.00 in net income (profit) each year or ($3.75) on an earnings per share basis.

How many employees does BridgeBio Pharma have?

The company employs 392 workers across the globe.

How can I contact BridgeBio Pharma?

BridgeBio Pharma's mailing address is 421 Kipling Street, Palo Alto CA, 94301. The official website for the company is bridgebio.com. The company can be reached via phone at (650) 391-9740.

This page (NASDAQ:BBIO) was last updated on 9/26/2023 by MarketBeat.com Staff

My Account -